The Drug Enforcement Administration (DEA) has formally requested that federal health officials conduct a medical scientific review on psilocybin in response to a long-pending rescheduling petition. After initially denying advocates’ request to authorize a review into the psychedelic, last week DEA forwarded the request to move psilocybin from Schedule I to Schedule II of the…...
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
